Pianzumab Combined With AVD Regimen in the Treatment of Newly-diagnosed Advanced Classic Hodgkin Lymphoma

NCT05949931 | Recruiting Phase 2

• 1 other identifier: B2023-092
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.

Conditions

Classic Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

• Complete response rate （CRR）

  Percentage of participants achieving complete response evaluated by the Independent Review Committee (IRC) at the end of all treatment courses

  From first injection to 24 weeks (Arm 1) From first injection to 48 weeks (Arm 2)

Secondary Outcomes (6)

• Complete response rate （CRR）

  From first injection to 24 weeks (Arm 1) From first injection to 48 weeks (Arm 2)

• Objective response rate（ORR）

  From first injection to 24 weeks (Arm 1) From first injection to 48 weeks (Arm 2)

• Progression-free Survival (PFS)

  Up to 5 years

• Modified progression-free survival (mPFS)

  Up to 5 years

• Overall survival (OS)

  Up to 5 years

Study Arms (2)

Concurrent penpulimab and AVD

EXPERIMENTAL

Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

Drug: Concurrent penpulimab and AVD

Sequential penpulimab and AVD

EXPERIMENTAL

Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

Drug: Sequential penpulimab and AVD

Interventions

Concurrent penpulimab and AVD DRUG

Participants will receive Penpulimab and AVD injection at the same time for a total of 6 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

Concurrent penpulimab and AVD

Sequential penpulimab and AVD DRUG

Participants will receive penpulimab for 3 cycles; follewed by 6 cycles of AVD; finally, penpulimab for 3 cycles. Cycle length = 28 days, Penpulimab and AVD will be administered on D1 and D15 of each cycle.

Sequential penpulimab and AVD

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: ≥18 years old (when signing the informed consent form); ECOG score: 0 or 1 point; The expected survival period exceeds 3 months;
• classic Hodgkin lymphoma (cHL) confirmed by histopathology;
• The subject must be advanced patient, specifically defined as Ann Arbor stage III-IV or IIB with any of the following high-risk factors: ① maximum diameter of mediastinal mass/maximum diameter of thoracic cavity\>0.33; ② There are large masses with a diameter of\>10cm;
• Have not received systemic anti classic Hodgkin lymphoma treatment;
• Measurable disease ;
• Adequate main organs function
• Female subjects of childbearing age should agree to use contraceptives (such as Intrauterine device, contraceptives or condoms) during the study period and within 6 months after the end of the study; The serum or urine Pregnancy test was negative within 7 days before the study was included, and must be non-lactating subjects; Male participants should agree to use contraception during the study period and within 6 months after the end of the study period.

You may not qualify if:

• Nodular lymphocyte dominated Hodgkin lymphoma or gray area lymphoma;
• Classic Hodgkin lymphoma involves the central nervous system;
• Subjects who have or are suspected to have active autoimmune diseases within the past 2 years, or have previously suffered from autoimmune diseases and are currently at high risk of recurrence and require systemic treatment；
• Subjects who need to use glucocorticoid (\>10mg/day prednisone Equivalent dose) or other immunosuppressive drugs for systemic treatment within 14 days before the first administration.
• Inoculate or expect to receive live or attenuated live vaccines or mRNA vaccines within 4 weeks before the first administration;
• Received allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;
• Known to have active pulmonary tuberculosis;
• Having a history of immunodeficiency, including HIV positive or suffering from other acquired or congenital immunodeficiency diseases;
• Subjects with a known history of interstitial pneumonia, a history of non-infectious pneumonia, or highly suspected cases of interstitial pneumonia;
• Patients with evidence of bleeding constitution or medical history; Within 4 weeks before the first medication, any ≥ CTC AE level 3 bleeding events (such as digestive tract bleeding, perforation, etc.) occur;
• Concomitant diseases and medical history:
• Has experienced or currently suffers from other malignant tumors within 3 years.
• Multiple factors affecting oral medicine (such as inability to swallow, chronic diarrhea and Bowel obstruction);
• Patients with a history of abuse of psychotropic substances who are unable to quit or have mental disorders;
• Subjects with any severe and/or uncontrollable disease.

Sponsors & Collaborators

• Sun Yat-sen University: lead

Study Sites (1)

Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University

Guangzhou, Guangdong, 510060, China

RECRUITING

Central Study Contacts

Qingqing Cai, MD. PhD.

CONTACT

0086-20-87342823; caiqq@sysucc.org.cn

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief physician

Study Record Dates

• First Submitted: July 10, 2023
• First Posted: July 18, 2023
• Study Start: October 1, 2023
• Primary Completion (Estimated): September 30, 2026
• Study Completion (Estimated): December 1, 2027
• Last Updated: May 1, 2026

Record last verified: 2026-04

Locations

CN (1)